skin inflammation

Westlake Village, California, August 20, 2026 Turn Therapeutics announced new peer-reviewed research providing in-vivo evidence that GX-03 selectively reduces...

WILMINGTON, Del., May 7, 2026 Incyte announced positive 24-week long-term results from the Phase 3 TRuE-AD4 clinical trial evaluating...